Weeks after $213M launch, Tome acquires a Berkeley gene editing startup for DNA ligase technology January 2, 2024
Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease December 19, 2023
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform December 12, 2023
